Rabbit Anti-Human Lyve-1

Slide this table

Cat-Nr.102-PABi50
Size50 µg
Price275 €
CategoryPolyclonal Antibody
LabelBiotin
Clone Nr.Rabbit IgG
Species ReactivityHuman
Formulationlyophilized
BufferPBS
Stabilizer/CarrierBSA (50x), 0.02% sodium azide
ReconstitutionCentrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Stability and StorageThe lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
PreparationProduced from sera of rabbits immunized with highly pure recombinant human soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1 consists of amino acid 24 (Ser) to 232 (Gly) and is fused to a C-terminal His-tag (6xHis). The antibody was purified via an antigen-affinity column and then biotinylated using a standard protocol.
AntigenRecombinant human sLYVE-1 (RT #S01-028)
ApplicationWB, FC
SynonymsLYVE1; HAR; XLKD1; LYVE-1; CRSBP-1
DescriptionLYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule co-localizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
Uniprot IDQ9Y5Y7
Protein RefSeqNP_006682
mRNA RefSeqNM_006691

Figures


Reference

  1. Generation of pure lymphatic endothelial cells from human pluripotent stem cells and their therapeutic effects on wound repair. Shin-Jeong Lee et al., Sci Rep. 2015; 5: 11019.
  2. Aberrant lymphatic development in euploid fetuses with increased nuchal translucency including Noonan syndrome. YM de Mooij et al., Prenat Diagn. 2011 Feb;31(2):159-66.

All prices plus VAT + possible delivery charges